Experience with basiliximab in pediatric liver graft recipients.
Ganschow
R
R
Department of Pediatrics, University of Hamburg, Hamburg, Germany.
Lyons
M
M
Grabhorn
E
E
Venzke
A
A
Broering
D C
DC
Rogiers
X
X
Hellwege
H H
HH
Burdelski
M
M
D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000077552:Basiliximab; D001835:Body Weight; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D016031:Liver Transplantation / Q000276:immunology*; D011183:Postoperative Complications / Q000453:epidemiology; D011239:Prednisolone / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D011239:Prednisolone